BioPharma Resources

Drugs by condition

Drugs approved for mash (fatty liver disease)

Brand-name prescription drugs and biologics whose FDA label lists mash (fatty liver disease) as an approved use. Matched on the label phrases: "steatohepatitis".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

2

Still marketed, NDA or BLA

Drug classes

2

Novel drugs

2

New molecular entities and new biologics

In development

29

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for mash (fatty liver disease).

  • Rezdiffra (Resmetirom) · Madrigal NovelBreakthrough therapyAccelerated approvalPriority reviewMar 14, 2024
  • Myalept (Metreleptin) · Chiesi Farmaceutici Spa NovelPriority reviewOrphanFeb 24, 2014

All approved drugs for mash (fatty liver disease), by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Thyroid Hormone Receptor beta Agonist (1)

Leptin Analog (1)

  • Myalept Metreleptin · Chiesi Farmaceutici Spa · 2014

Drugs in development for mash (fatty liver disease)

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • HRS9531Phase 313 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)

  • UBT251Phase 310 trials

    The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2

  • IBI362Phase 38 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Obesity, Overweight, Sleep Apnea

  • EfimosferminBOS-580Phase 37 trials

    GSK · Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic

  • Saroglitazar MagnesiumPhase 35 trials

    Zydus Therapeutics Inc. · Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Fibrosis

  • ALN-CIDEBPhase 34 trials

    Regeneron · Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD

  • HTD1801Berberine UrsodeoxycholatePhase 34 trials

    Shenzhen HighTide Biopharmaceutical Ltd. · T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes

  • PemvidutidePhase 34 trials

    Altimmune, Inc. · Alcohol-associated Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD)

  • EfruxiferminPhase 33 trials

    Akero Therapeutics, Inc · NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH/MASH

  • pegargiminaseADI-PEG 20Phase 33 trials

    Polaris Group · Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma

  • PegozaferminBIO89-100Phase 33 trials

    Roche (Genentech) · Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Severe Hypertriglyceridemia

  • HSK31679Phase 32 trials

    Haisco Pharmaceutical Group Co., Ltd. · MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH (Non-Alcoholic Steatohepatitis), Non-Alcoholic Steatohepatitis (NASH)

  • IVA337LanifibranorPhase 31 trial

    Inventiva Pharma · NASH - Nonalcoholic Steatohepatitis

  • HRS-4729Phase 23 trials

    Fujian Shengdi Pharmaceutical Co., Ltd. · Metabolic Dysfunction-Associated Steatohepatitis (MASH), Type 2 Diabetes, Overweight or Obesity

  • ARO-INHBEPhase 22 trials

    Arrowhead Pharmaceuticals · Metabolic Dysfunction-Associated Steatohepatitis, Obesity

  • ECC4703Phase 22 trials

    Eccogene · Adult Obesity, Weight Management, Metabolic Dysfunction-associated Steatohepatitis

  • EfinopegdutideMK-6024, HM12525APhase 22 trials

    Merck & Co. · Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic

  • HU6Phase 22 trials

    Rivus Pharmaceuticals, Inc. · Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver

  • NNC0194-0499Phase 22 trials

    Novo Nordisk · Alcohol-related Liver Disease, Non-alcoholic Steatohepatitis

  • AZD2693Phase 21 trial

    AstraZeneca · Nonalcoholic Steatohepatitis

More on mash (fatty liver disease): recruiting trials · published research

Related in gastroenterology and liver: Primary biliary cholangitis · Acid reflux (GERD) · Irritable bowel syndrome · Chronic constipation · Nausea and vomiting · Eosinophilic esophagitis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.